XML 33 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
Equity Method Accounting for Common Stock of Asterias, at fair value (Tables)
 3 Months Ended
Mar. 31, 2017
Asterias Biotherapeutics [Member]  
Equity Method Accounting for Common Stock of Asterias, at fair value [Abstract]  
Unaudited results of operations and condensed balance sheet information
The unaudited condensed results of operations for the three months ended March 31, 2017 and 2016, the unaudited condensed balance sheet information of Asterias at March 31, 2017 and the audited balance sheet information of Asterias at December 31, 2016 are summarized below (in thousands):

  
Three Months
Ended March 31,
2017
(unaudited)
  
Three months
ended March 31,
2016
(unaudited)
 
Condensed Statements of Operations (1):
      
Total revenue
 
$
2,010
  
$
1,594
 
Gross profit
  
1,957
   
1,541
 
Loss from operations
  
(9,107
)
  
(11,016
)
Net loss
 
$
(6,287
)
 
$
(10,262
)

  
March 31, 2017
(unaudited)
  
December 31, 2016
 
Condensed Balance Sheet information (2):
      
Current assets
 
$
34,164
  
$
36,990
 
Noncurrent assets
  
23,057
   
24,020
 
  
$
57,221
  
$
61,010
 
         
Current liabilities
 
$
2,883
  
$
6,051
 
Noncurrent liabilities
  
9,876
   
12,930
 
Stockholders’ equity
  
44,462
   
42,029
 
  
$
57,221
  
$
61,010